Regulatory Coordination Clause Samples

Regulatory Coordination. The Parties shall cooperate in (i) analyzing and reacting to pending material Applicable Law changes and discussing regulatory developments affecting the Program, including any of the Financial Products or Accounts established thereunder, and (ii) subject to Applicable Law regarding the confidentiality of Bank supervisory matters, responding to Regulatory Authorities regarding regulatory-related requests to the Parties.

Regulatory Coordination. (i) The Lead Regulatory Party shall oversee, monitor and coordinate all regulatory actions, communications and filings with and submissions, including filings and submissions of supplements and amendments thereto, to each applicable Regulatory Authority with respect to each Product. The Lead Regulatory Party shall perform all such activities in accordance with the Joint Steering Committee-approved Development Plan, relevant Country Co-Commercialization Plans and pricing strategies and guidelines. (ii) The Parties shall establish procedures to ensure that the Parties exchange on a timely basis all necessary information to enable the Lead Regulatory Party to comply with all regulatory obligations on a global basis, including, without limitation, filing updates, pharmacovigilance filings and investigator notifications. The Parties shall provide to each other prompt notice of any approved Registration Filing.

Regulatory Coordination. (a) The Lead Regulatory Party shall oversee, monitor and coordinate all regulatory actions, communications and filings with and submissions (including supplements and amendments thereto) to each applicable Regulatory Authority with respect to the VEGF Product in the jurisdiction as to which it is the Lead Regulatory Party; provided that it shall adhere to the obligations in this Article 7. The Lead Regulatory Party shall perform all such activities in accordance with the Co-Development Plans, Global Co-Commercialization Plans, applicable Country Co-Commercialization Plans, and all applicable Laws. (b) The Parties shall establish procedures to ensure that the Parties exchange on a timely basis all necessary information to enable the Lead Regulatory Party to comply with all regulatory obligations on a global basis, including, without limitation, filing updates or supplements with Regulatory Authorities, pharmacovigilance filings, manufacturing supplements, and investigator notifications to Regulatory Authorities. The Parties shall provide to each other prompt written notice of any Approval of a VEGF

Regulatory Coordination. (a) The Parties acknowledge and agree that beginning with the First Amendment Effective Date, neither Sanofi nor its Affiliates shall have any interest or rights whatsoever in or to any (i) biologics license application (as described in FDA regulations, including all amendments and supplements to the application and any equivalent filing with a Regulatory Authority (“BLA(s)”), (ii) investigational new drug applications (as described in FDA regulations, including all amendments and supplements to the application and any equivalent filing with any Regulatory Authority outside of the United States (“IND(s)”), (iii) registration filings to the relevant Regulatory Authority of an appropriate application seeking any Approval (“Registration Filings”), and (iv) any Approvals, in each of (i) through (iv) for any Excluded Ocular ANG2 Products, except as set forth in Section 10(c) of this First Amendment. There is no Lead Regulatory Party or non-Lead Regulatory Party for the Excluded Ocular ANG2 Products. For the purposes of this Section 10, “Approvals” shall mean, with respect to the applicable ANG2 Licensed Product or Excluded Ocular ANG2 Product, as the case may be, any marketing approvals, pricing approvals, registration, license or authorization from any Regulatory Authority required for the development, manufacture or commercialization of such product in the Field or Excluded Field, as the case may be, in a regulatory jurisdiction anywhere in the world, and shall include, without limitation, any approval, registration, license or authorization granted in connection with any Registration Filing. (b) Regeneron and its Affiliates and licensees shall have, and Sanofi and its Affiliates hereby grant to Regeneron and its Affiliates and licensees, the right to reference the BLA(s), IND(s), and any Registration Filings and/or Approvals for any ANG2 Licensed Product requested by Regeneron to support Regeneron' s (and its Affiliates' and licensees', as applicable) IND, BLA, Registration Filings and/or Approvals for Excluded Ocular ANG2 Products anywhere in the world. Promptly upon the request of Regeneron, Sanofi or its Affiliate shall submit a letter of authorization to FDA or the applicable Regulatory Authority (and take such actions or make such other filings) in order to permit any ANG2 Licensed Product IND, BLA, Registration Filing and/or Approval to be incorporated by reference in such Excluded Ocular ANG2 Product regulatory filings. (c) Sanofi and its Affiliates a...

Regulatory Coordination. IMPH will have exclusive control over, and authority and responsibility for, the regulatory strategies relating to the development and commercialization of all Licensed Products for use in the Licensed Field, including, without limitation (i) the preparation of all documents submitted to Competent Authorities and the filing of all INDs, Drug Approval Applications and other submissions relating to Licensed Products and (ii) all regulatory actions, communications and meetings with any Regulatory Authority with respect to any Licensed Products in the Licensed Field. IMPH shall use Reasonable Endeavors to prepare, file and prosecute all regulatory filings as needed to obtain Marketing Approvals of Licensed Product as soon as practicable in each country in the Territory where it is commercially reasonable to market Licensed Product. Subject to any confidentiality obligations to Third Parties, each Party shall provide to the other Party on a timely basis all information controlled by such Party or otherwise in such Party’s possession as a result of its activities under this Agreement that is necessary for the other Party to comply with all regulatory obligations on a global basis applicable to Licensed Products (in the case of IMPH) or Ocular Products (in the case of iCo), including filing updates, information amendments, annual reports, pharmacovigilance filings, preclinical research data, preclinical study reports, investigator notifications and chemistry, manufacturing and controls information in relation to iCo-008, the Licensed Product or Ocular Product, each of the foregoing to the extent necessary for the other Party. For clarity, IMPH is responsible for all adverse event and other safety reporting worldwide with respect to Licensed Products. All updates and reports provided hereunder shall be provided in a form as reasonably required by each Party for inclusion in any regulatory submission. IMPH shall be responsible for interfacing, corresponding and meeting with all Regulatory Authorities with respect to any Licensed Product. The Parties shall cooperate with each other to provide all reasonable assistance and take all actions reasonably requested by the other Party that are necessary to comply with any law applicable to any Licensed Product and Ocular Product, as the case may be, including, but not limited to, providing the other Party with reasonable access during ordinary business hours and upon reasonable written notice to its personnel, as reasonabl...

Regulatory Coordination. 5.2.1 As further specified in Sections 5.3 and 5.4, Amgen shall oversee, monitor and coordinate all regulatory actions, communications and filings with and submissions to regulatory authorities, including filings and submissions of supplements and amendments thereto, with respect to each Amgen Development Compound or Amgen Development Product unless otherwise determined by Amgen. 5.2.2 As further specified in Sections 5.3 and 5.4, Tularik shall oversee, monitor and coordinate all regulatory actions, communications and filings with and submissions to regulatory authorities, including filings and submissions of supplements and amendments thereto, with respect to each TD Product, Tularik Target Product and Tularik Exclusive Product.

Regulatory Coordination. 5.2.1 The Lead Regulatory Party shall oversee, monitor and coordinate all regulatory actions, communications and filings with and submissions, including filings and submissions of supplements and amendments thereto, to the FDA or HPB with respect to the relevant Joint Development Compound or Joint Development Product. Aventis shall oversee, monitor and coordinate all regulatory actions, communications and filings with and submissions to, including filings and submissions of supplements and amendments thereto, regulatory authorities outside of North America with respect to the relevant Joint Development Compound or Joint Development Product unless otherwise determined by the Joint Development Committee. 5.2.2 In the event that Millennium is the Lead Regulatory Party, the Parties shall establish procedures to ensure that the Parties exchange on a timely basis all necessary information to enable compliance with all regulatory obligations on a global basis, including without limitation filing updates, pharmacovigilance filings and investigator notifications.

Regulatory Coordination. (a) Lung Rx shall be responsible for preparing, filing and managing all regulatory filings and efforts seeking all Regulatory Approvals in the Territory. All regulatory filings for the Product in the Territory shall be filed in the name of Lung Rx, and Lung Rx alone shall be responsible for all communications and other dealings with Regulatory Authorities relating to the Product in the Territory. As between the Parties, Lung Rx shall be the sole and exclusive legal and beneficial owner of all regulatory applications, clinical data, Regulatory Dossiers and Regulatory Approvals in the Territory. Lung Rx shall have the final authority to make all clinical and regulatory decisions with respect to the registration of Products within the Territory in its sole discretion. Lung Rx shall have the right to reference any of Aradigm’s regulatory files Controlled by Aradigm relating to the AERx pulmonary drug delivery system, in connection with regulatory filings made by or on behalf of Lung Rx and Aradigm shall reasonably cooperate with Regulatory Authorities in connection therewith. (b) The PSC shall develop and implement procedures for drafting and review of any applications for Regulatory Approval for the Product in the Territory, which shall provide sufficient time for Aradigm to provide substantive comments. Unless otherwise agreed upon by the Parties, Aradigm shall provide any comments it may have to Lung Rx within 20 days of its receipt of each application. Lung Rx shall consider Aradigm’s comments on any such applications in good faith; provided, however, that Lung Rx shall have the right to make all final decisions relating to the content of each such application. (c) Lung Rx shall promptly notify Aradigm of all regulatory filings that it submits and all communications from Regulatory Authorities that it receives relating to Products, and shall promptly provide Aradigm with a copy (which may be wholly or partly in electronic form) of such regulatory filings or communications. Lung Rx will provide Aradigm with reasonable advance notice of any scheduled meetings with any regulatory agencies relating to Development and/or any application for Regulatory Approval of the Product in the Territory, and Aradigm shall have the right to participate in any such meeting, to the extent permitted by law. Lung Rx also shall promptly furnish Aradigm with summaries of all material correspondence or material meetings with any regulatory agency relating to Development, regulator...

Regulatory Coordination. Responding to inquiries and information requests from the DTSC. These responses may include additional sampling or laboratory analyses or other data acquisition. Analysis of existing data may also be required. • RMP Implementation Support: Support for activities necessary to be implemented as part of the RMP for Site A associated with work at the project area. • Prepare Tasks for ROPS Funding Cycle 2025/2026: EKI will prepare a proposal for the ROPS 2025/2026 funding cycle (1 July 2025 through 30 June 2026) based upon the progress of the project in 2024.